MX2021003119A - Anticuerpos anti-klrg1. - Google Patents
Anticuerpos anti-klrg1.Info
- Publication number
- MX2021003119A MX2021003119A MX2021003119A MX2021003119A MX2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A MX 2021003119 A MX2021003119 A MX 2021003119A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- klrg1
- antigen
- binding fragments
- klrg1 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732329P | 2018-09-17 | 2018-09-17 | |
| PCT/US2019/050110 WO2020060781A1 (en) | 2018-09-17 | 2019-09-06 | Anti-klrg1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003119A true MX2021003119A (es) | 2021-05-14 |
Family
ID=69887899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003119A MX2021003119A (es) | 2018-09-17 | 2019-09-06 | Anticuerpos anti-klrg1. |
| MX2025008993A MX2025008993A (es) | 2018-09-17 | 2021-03-16 | Anticuerpos anti-klrg1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025008993A MX2025008993A (es) | 2018-09-17 | 2021-03-16 | Anticuerpos anti-klrg1 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12365735B2 (enExample) |
| EP (1) | EP3852779A4 (enExample) |
| JP (2) | JP7654548B2 (enExample) |
| KR (1) | KR102934267B1 (enExample) |
| CN (2) | CN112752580B (enExample) |
| AU (1) | AU2019344524B2 (enExample) |
| BR (1) | BR112021004553A2 (enExample) |
| CA (1) | CA3113069A1 (enExample) |
| EA (1) | EA202190647A1 (enExample) |
| IL (2) | IL281594B2 (enExample) |
| MX (2) | MX2021003119A (enExample) |
| SG (1) | SG11202102114UA (enExample) |
| WO (1) | WO2020060781A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3852779A4 (en) | 2018-09-17 | 2022-06-08 | Abcuro, Inc. | ANTI-KLRG1 ANTIBODIES |
| US20230331853A1 (en) * | 2020-09-11 | 2023-10-19 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| CA3212311A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| US20260103525A1 (en) * | 2022-09-27 | 2026-04-16 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2595169A1 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| CA2673870A1 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| WO2011016238A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| EP2611832B1 (en) * | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| EP2699256B1 (en) | 2011-04-21 | 2017-09-27 | The Regents of the University of Colorado, a body corporate | Compositions and methods for the treatment of neuromyelitis optica |
| ES2929575T3 (es) | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
| JPWO2012176765A1 (ja) * | 2011-06-24 | 2015-02-23 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| TW201622743A (zh) | 2014-03-19 | 2016-07-01 | 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 | 免疫原醣肽、包含該醣肽之組合物及其用途 |
| WO2016009487A1 (ja) | 2014-07-14 | 2016-01-21 | 三菱電機株式会社 | 空気調和装置 |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| PE20181349A1 (es) | 2015-10-07 | 2018-08-22 | Hoffmann La Roche | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| JP7023853B2 (ja) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗ｔｒｅｍ１抗体及びその使用方法 |
| CA3026182A1 (en) | 2016-06-03 | 2017-12-07 | Steven Greenberg | Klrg1 signaling therapy |
| AU2017326003A1 (en) | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CA3059938A1 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
| WO2018237341A1 (en) | 2017-06-22 | 2018-12-27 | Development Center For Biotechnology | A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY |
| US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
| EP3852779A4 (en) | 2018-09-17 | 2022-06-08 | Abcuro, Inc. | ANTI-KLRG1 ANTIBODIES |
| MX2021012171A (es) | 2019-04-09 | 2021-12-10 | Abcuro Inc | Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1). |
| CA3212311A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
-
2019
- 2019-09-06 EP EP19862063.5A patent/EP3852779A4/en active Pending
- 2019-09-06 AU AU2019344524A patent/AU2019344524B2/en active Active
- 2019-09-06 CA CA3113069A patent/CA3113069A1/en active Pending
- 2019-09-06 KR KR1020217008068A patent/KR102934267B1/ko active Active
- 2019-09-06 EA EA202190647A patent/EA202190647A1/ru unknown
- 2019-09-06 IL IL281594A patent/IL281594B2/en unknown
- 2019-09-06 CN CN201980060735.4A patent/CN112752580B/zh active Active
- 2019-09-06 CN CN202411978380.6A patent/CN119638835A/zh active Pending
- 2019-09-06 BR BR112021004553-8A patent/BR112021004553A2/pt unknown
- 2019-09-06 SG SG11202102114UA patent/SG11202102114UA/en unknown
- 2019-09-06 US US17/285,793 patent/US12365735B2/en active Active
- 2019-09-06 MX MX2021003119A patent/MX2021003119A/es unknown
- 2019-09-06 WO PCT/US2019/050110 patent/WO2020060781A1/en not_active Ceased
- 2019-09-06 JP JP2021539334A patent/JP7654548B2/ja active Active
-
2021
- 2021-03-16 MX MX2025008993A patent/MX2025008993A/es unknown
-
2024
- 2024-08-02 JP JP2024127876A patent/JP2024156878A/ja active Pending
-
2025
- 2025-06-10 US US19/233,441 patent/US20260125479A1/en active Pending
- 2025-09-04 IL IL323170A patent/IL323170A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020060781A1 (en) | 2020-03-26 |
| SG11202102114UA (en) | 2021-04-29 |
| IL281594B1 (en) | 2025-10-01 |
| US20210347899A1 (en) | 2021-11-11 |
| BR112021004553A2 (pt) | 2021-06-08 |
| JP2022501065A (ja) | 2022-01-06 |
| MX2025008993A (es) | 2025-09-02 |
| KR20210060477A (ko) | 2021-05-26 |
| KR102934267B1 (ko) | 2026-03-05 |
| JP2024156878A (ja) | 2024-11-06 |
| EP3852779A4 (en) | 2022-06-08 |
| EP3852779A1 (en) | 2021-07-28 |
| EA202190647A1 (ru) | 2021-09-09 |
| US12365735B2 (en) | 2025-07-22 |
| IL323170A (en) | 2025-11-01 |
| US20260125479A1 (en) | 2026-05-07 |
| IL281594B2 (en) | 2026-02-01 |
| IL281594A (en) | 2021-05-31 |
| JP7654548B2 (ja) | 2025-04-01 |
| CN112752580B (zh) | 2024-12-13 |
| AU2019344524B2 (en) | 2026-07-09 |
| CN119638835A (zh) | 2025-03-18 |
| CN112752580A (zh) | 2021-05-04 |
| AU2019344524A1 (en) | 2021-03-25 |
| CA3113069A1 (en) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000370A (es) | Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos | |
| CL2020003096A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| MX392098B (es) | Anticuerpos neutralizantes de poliomavirus. | |
| MX2017006167A (es) | Compuestos que interactúan con glicanos y métodos de uso. | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| MX2017002230A (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| UA123202C2 (uk) | Антитіло до тау-білка і його застосування | |
| EA202190647A1 (ru) | Антитела к klrg1 | |
| EA202091315A3 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
| MX2015016978A (es) | Proteinas de union a antigeno neutralizantes de citomegalovirus. | |
| MX2017006448A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139). | |
| PE20170258A1 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos | |
| CL2021001615A1 (es) | Anticuerpos anti il-36 y procedimientos de uso de estos | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| CO2018004569A2 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| CO2019002550A2 (es) | Anticuerpos anti-gm-csf y usos de los mismos |